Sulforaphane Diminishes the Formation of Mammary Tumors in Rats Exposed to 17β-Estradiol.

Détails

ID Serval
serval:BIB_AFF6BBE45853
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Sulforaphane Diminishes the Formation of Mammary Tumors in Rats Exposed to 17β-Estradiol.
Périodique
Nutrients
Auteur⸱e⸱s
Palliyaguru D.L., Yang L., Chartoumpekis D.V., Wendell S.G., Fazzari M., Skoko J.J., Liao Y., Oesterreich S., Michalopoulos G.K., Kensler T.W.
ISSN
2072-6643 (Electronic)
ISSN-L
2072-6643
Statut éditorial
Publié
Date de publication
30/07/2020
Peer-reviewed
Oui
Volume
12
Numéro
8
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Elevated levels of estrogen are a risk factor for breast cancer. In addition to inducing DNA damage, estrogens can enhance cell proliferation as well as modulate fatty acid metabolism that collectively contributes to mammary tumorigenesis. Sulforaphane (SFN) is an isothiocyanate derived from broccoli that is currently under evaluation in multiple clinical trials for prevention of several diseases, including cancer. Previous studies showed that SFN suppressed DNA damage and lipogenesis pathways. Therefore, we hypothesized that administering SFN to animals that are co-exposed to 17β-estradiol (E2) would prevent mammary tumor formation. In our study, 4-6 week old female August Copenhagen Irish rats were implanted with slow-release E2 pellets (3 mg x 3 times) and gavaged 3x/week with either vehicle or 100 μmol/kg SFN for 56 weeks. SFN-treated rats were protected significantly against mammary tumor formation compared to vehicle controls. Mammary glands of SFN-treated rats showed decreased DNA damage while serum free fatty acids and triglyceride species were 1.5 to 2-fold lower in SFN-treated rats. Further characterization also showed that SFN diminished expression of enzymes involved in mammary gland lipogenesis. This study indicated that SFN protects against breast cancer development through multiple potential mechanisms in a clinically relevant hormonal carcinogenesis model.
Mots-clé
Animals, Anticarcinogenic Agents/pharmacology, Cell Proliferation/drug effects, DNA Damage/drug effects, Estradiol, Fatty Acids/blood, Female, Isothiocyanates/pharmacology, Lipogenesis/drug effects, Mammary Neoplasms, Animal/chemically induced, Mammary Neoplasms, Animal/prevention & control, Mammary Neoplasms, Experimental/chemically induced, Mammary Neoplasms, Experimental/prevention & control, Rats, Sulfoxides, Triglycerides/blood, breast cancer, estrogen, lipid metabolism, prevention, sulforaphane
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/09/2023 19:25
Dernière modification de la notice
23/09/2023 5:55
Données d'usage